Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 16 07 2018
accepted: 13 02 2019
entrez: 8 3 2019
pubmed: 8 3 2019
medline: 18 12 2019
Statut: epublish

Résumé

Barriers to achieve sustained HIV virological suppression on antiretroviral therapy (ART) jeopardize the success of the 90:90:90 UNAIDS initiative which aims to end the HIV/AIDS epidemic. In France, where access to ART is free and universally available, we analyze the way in which social determinants of health (i.e. cultural, environmental) and economic factors might influence virological outcomes. A cross-sectional study was performed in two hospitals located in Paris area. All consecutive people living with HIV (PLHIV) on ART for at least 6 months attending the outpatient clinics between 01/05/2013 and 31/10/2014 answered an individual score of deprivation, EPICES, retrieving information on health insurance status, economic status, family support and leisure activity. This score varies from 0 to 100 with deprivation state defined above 30.17. Factors associated with HIV viral load >50 copies/ml were assessed by logistic regression modeling with a backward stepwise selection to select the final multivariable model. Sensitivity analyses were performed using two other thresholds for virological non-suppression (100 or 200 copies/ml). Overall, 475 PLHIV were included (53% male, median age 47 years, 66% not born in France mainly in a sub-Saharan African country). Half of French natives and 85% of migrants were classified as deprived. Median duration on ART was 9.7 years with virological suppression in 95.2% of non-deprived participants and in 83.5% of deprived ones (p = 0.001). The final multivariable model retained ART tiredness, younger age, a previous AIDS event and social deprivation (adjusted Odds Ratio, 2.9; 95%CI, 1.2-7.0) as determinants of virological non-suppression but not migration in itself. When using separate components of EPICES score, reporting economic difficulties and non-homeownership were associated with virological non-suppression. In addition to interventions focusing on cultural aspects of migration, social interventions are needed to help people with social vulnerability to obtain sustained responses on ART.

Identifiants

pubmed: 30845270
doi: 10.1371/journal.pone.0213019
pii: PONE-D-18-21069
pmc: PMC6405133
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0213019

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

AIDS. 2017 Jan 14;31(2):253-262
pubmed: 27662557
Antivir Ther. 2016;21(8):661-670
pubmed: 27355137
AIDS. 2016 May 15;30(8):1147-62
pubmed: 26919732
J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):79-85
pubmed: 21937923
AIDS. 2015 Jan 28;29(3):373-83
pubmed: 25686685
HIV Med. 2018 Jan;19(1):42-48
pubmed: 28741837
AIDS Behav. 2012 Feb;16(2):245-55
pubmed: 21630013
Lancet HIV. 2017 Nov;4(11):e475
pubmed: 29096785
PLoS One. 2015 Mar 03;10(3):e0118492
pubmed: 25734445
Lancet Public Health. 2016 Nov;1(1):e26-e36
pubmed: 28299369
AIDS. 2007 Jan;21 Suppl 1:S5-12
pubmed: 17159588
Eur J Public Health. 2015 Aug;25(4):604-9
pubmed: 25624273
AIDS Care. 2017 Jan;29(1):105-111
pubmed: 27334840
AIDS. 2015 Jan 14;29(2):231-8
pubmed: 25396262
PLoS One. 2017 Mar 6;12(3):e0173338
pubmed: 28264016
AIDS. 2017 Mar 27;31(6):835-846
pubmed: 28272136
AIDS. 2016 Sep 10;30(14):2235-46
pubmed: 27428741
AIDS. 2015 Jan 14;29(2):239-40
pubmed: 25532608
HIV Med. 2007 Apr;8(3):164-70
pubmed: 17461860
HIV Med. 2018 Mar;19(3):238-242
pubmed: 28834136
J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):205-12
pubmed: 27105049
Curr Opin HIV AIDS. 2016 Sep;11(5):501-506
pubmed: 27272536
HIV Med. 2013 May;14(5):273-83
pubmed: 23171059

Auteurs

Mariem Raho-Moussa (M)

AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France.

Marguerite Guiguet (M)

Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.

Céline Michaud (C)

AP-HP, Hôpital Avicenne, Service de Maladies Infectieuses et Tropicales, Bobigny, France.

Patricia Honoré (P)

AP-HP, Hôpital Avicenne, Service de Maladies Infectieuses et Tropicales, Bobigny, France.

Christia Palacios (C)

AP-HP, Hôpital Avicenne, Service de Maladies Infectieuses et Tropicales, Bobigny, France.

François Boué (F)

AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France.
Université Paris-Saclay, Univ. Paris-Sud, UVSQ, Le Kremlin-Bicêtre, France.

Mohammed Azghay (M)

AP-HP, Hôpital Avicenne, Service de Maladies Infectieuses et Tropicales, Bobigny, France.

Imad Kansau (I)

AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France.

Véronique Chambrin (V)

AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France.

Tania Kandel (T)

AP-HP, Hôpital Avicenne, Service de Maladies Infectieuses et Tropicales, Bobigny, France.

Marion Favier (M)

AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France.

Elsa Miekoutima (E)

AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France.

Naomi Sayre (N)

AP-HP, Hôpital Avicenne, Service de Maladies Infectieuses et Tropicales, Bobigny, France.

Carole Pignon (C)

AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France.

Michka Shoai (M)

AP-HP, Hôpital Avicenne, Service de Maladies Infectieuses et Tropicales, Bobigny, France.

Olivier Bouchaud (O)

AP-HP, Hôpital Avicenne, Service de Maladies Infectieuses et Tropicales, Bobigny, France.
Université Paris 13, Bobigny, France.

Sophie Abgrall (S)

AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France.
Université Paris-Saclay, Univ. Paris-Sud, UVSQ, Le Kremlin-Bicêtre, France.
CESP INSERM U1018, Le Kremlin-Bicêtre, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH